[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536412":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":19,"armGroups":11,"interventions":11,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":47,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":11,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":11,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Power Life Sciences Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Rate of patients in clinical research for scleroderma",null,"3 months",{"measure":14,"description":11,"timeFrame":15},"Number of scleroderma study participants who stay committed until clinical study wraps up","12 months",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":17,"timePerspective":18,"maskingInfo":11},"CASE_CROSSOVER","PROSPECTIVE","Patients diagnosed with scleroderma who are actively considering participation in a clinical trial for this ailment, but have not yet concluded the enrollment and randomization phases.",[21],{"name":22,"affiliation":5,"role":23},"Michael B Gill","STUDY_DIRECTOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":28},"CONTACT","4159004227","bask@withpower.com",[30],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Power Life Sciences","San Francisco","California","94107","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-122.41942,37.77493,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":45,"phoneExt":11,"email":46},"415-900-4227","https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100536412",false,"NCT06264492","Delving Into Participation Trends of Scleroderma Clinical Trials","Deciphering Patient Participation: Insights From Observational Data in Scleroderma Clinical Trials","Inclusion Criteria:\n\n* Patient has been diagnosed with scleroderma\n* Patient has self-identified as planning to enroll in an observational clinical trial\n* Patient is a minimum of 18 years or older\n\nExclusion Criteria:\n\n* Patient is pregnant\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form","ALL","18 Years",{"count":58,"type":59},500,"ESTIMATED","OBSERVATIONAL","Typically, specific demographic subsets tend to exhibit greater engagement in medical research. Nonetheless, there is insufficient research elucidating the trial characteristics influencing the participation of these particular demographics.\n\nThe study will analyze data from diverse demographic viewpoints to uncover recurring trends that could provide valuable insights for future patients with scleroderma.",[63],"Scleroderma",[65],"scleroderma","NOT_YET_RECRUITING","2024-02-23",{"date":69,"type":70},"2024-02-28","ACTUAL",{"date":72,"type":59},"2025-03",{"date":74,"type":59},"2027-03",{"name":5,"class":6},1]